Every 424B that Soligenix, Inc. (SNGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNGX filings page.
Soligenix, Inc. filed a prospectus supplement covering the offer and sale by the company of 5,330,560 shares of common stock underlying previously issued common warrants, and incorporated its Quarterly Report for the period ended June 30, 2026. The company operates two segments, Specialized BioTherapeutics and Public Health Solutions, and remains a development-stage biopharmaceutical business with no grant or product revenue in the quarter.
For the three months ended June 30, 2026, Soligenix reported a net loss of $1.99 million (basic and diluted loss per share $0.12), versus $2.70 million in the prior-year quarter. For the first six months of 2026, net loss was $4.81 million versus $5.65 million a year earlier. Cash and cash equivalents were $9.81 million at June 30, 2026, up from $7.94 million at December 31, 2025, aided by $6.04 million of gross proceeds from at-the-market equity sales under the Rodman Sales Agreement.
Management reports working capital of $6.50 million and believes existing cash can fund operations into the second quarter of 2028, yet nonetheless states that substantial doubt exists about the company’s ability to continue as a going concern, as strategic alternatives and additional program assets have not been secured. In April 2026 an interim analysis led to a recommendation to halt the FLASH2 Phase 3 trial of HyBryte for cutaneous T-cell lymphoma for futility, and the Board terminated the HyBryte development program in June 2026. On June 10, 2026, Soligenix received a Nasdaq notice for non-compliance with the $1.00 minimum bid price requirement and has until December 7, 2026 to regain compliance, with the possibility of an additional 180-day extension or a delisting process thereafter.
Soligenix, Inc. filed a prospectus supplement covering 408,640 shares of common stock issuable upon exercise of previously issued common warrants and incorporated its Quarterly Report for the period ended June 30, 2026. The company reported no revenue and a six‑month net loss of $4,812,319, driven by $2,756,391 in research and development and $2,227,910 in general and administrative expenses.
Cash and cash equivalents were $9,811,141, with working capital of $6,499,947. Management projects cash runway into the second quarter of 2028 but still concluded there is substantial doubt about its ability to continue as a going concern. The Board terminated the HyBryte™ CTCL program after a Phase 3 trial was halted for futility. Soligenix is funding operations partly through a Rodman at‑the‑market facility, having sold about $6.234 million of stock by June 30, 2026, and faces a Nasdaq minimum bid price deficiency with a compliance deadline of December 7, 2026.
Soligenix, Inc. is registering 4,253 shares of common stock underlying previously issued common warrants under a shelf prospectus, while also presenting its Quarterly Report for the period ended June 30, 2026.
For Q2 2026, the company reported no revenue and a net loss of $1,987,354, with a six‑month net loss of $4,812,319. Cash and cash equivalents were $9,811,141, and total assets $10,499,470. Shareholders’ equity was $6,645,557 with an accumulated deficit of $249,863,451. Shares outstanding increased to 21,765,479 as of July 31, 2026, driven largely by at‑the‑market (ATM) equity sales.
Management states it has cash runway into the second quarter of 2028, yet also concludes that substantial doubt exists about the company’s ability to continue as a going concern without additional strategic transactions or financing. The lead HyBryte™ program for cutaneous T‑cell lymphoma was terminated in June 2026 after a Phase 3 trial was recommended to halt for futility. In June 2026, Soligenix received a Nasdaq bid‑price deficiency notice, with until December 7, 2026 to regain compliance, potentially via actions such as a reverse stock split.
Soligenix, Inc. filed a prospectus supplement covering the resale of up to 1,054,688 shares of common stock issuable upon exercise of previously issued warrants by selling stockholders. The supplement incorporates the company’s Form 10‑Q for the quarter ended June 30, 2026.
As of June 30, 2026, Soligenix reported cash and cash equivalents of $9.8 million, total assets of $10.5 million, and shareholders’ equity of $6.6 million. The company generated no revenue and recorded a net loss of $1.99 million for the quarter and $4.81 million for the first half of 2026, with an accumulated deficit of $249.9 million. Working capital was $6.5 million, and management projects cash runway into the second quarter of 2028, yet still concluded there is substantial doubt about its ability to continue as a going concern.
Soligenix expanded its Rodman at-the-market facility, selling approximately $6.23 million of common stock through June 30, 2026 and retaining about $2.4 million of remaining capacity as of July 31, 2026. Shares outstanding increased to 21.6 million at June 30, 2026 and 21.8 million at July 31, 2026. In June 2026, the Board terminated the HyBryte™ CTCL development program after a Phase 3 trial was halted for futility, and the related FDA orphan grant study was wound down. The company also disclosed a Nasdaq bid-price deficiency notice received in June 2026, with until December 7, 2026 to regain compliance.
Soligenix, Inc. amends its prior prospectus supplements to reset the available At-The-Market capacity under its Sales Agreement with Rodman & Renshaw LLC to $2,500,000. This Prospectus Supplement replaces unsold amounts under the Prior Prospectus and permits the company to offer and sell common stock from time to time under the Sales Agreement.
The Prior Prospectus had authorized up to an aggregate offering price of $6,406,000, of which shares with an aggregate price of approximately $6,234,000 were sold. The company reports a public float of $30,702,784 based on 21,621,679 shares held by non-affiliates and a per-share price of $1.42 as of April 27, 2026. Pursuant to Form S-3 General Instruction I.B.6, Soligenix discloses it has sold securities with an aggregate market value of $7,700,914 in the prior 12-calendar-month period.
Soligenix, Inc. amends its prospectus supplement to set an at-the-market offering capacity of $2,956,000 of common stock under the Sales Agreement with Rodman & Renshaw LLC. The company reports a public float of $24,511,625 based on 17,261,708 shares held by non-affiliates at $1.42 per share as of April 27, 2026. The supplement notes prior sales of $5,214,498 under the Form S-3 instruction during the preceding 12-month period and lists a last reported sale price of $0.87 on May 27, 2026.
Soligenix, Inc. files a Prospectus Supplement No. 1 dated May 8, 2025, registering 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 and updates the Final Prospectus. As of May 1, 2026, shares outstanding were 14,824,174. The Form 10-Q shows cash of $6,029,430, a net loss of $(2,824,965) for the quarter, and management discloses that substantial doubt exists about the Company’s ability to continue as a going concern; management expects cash runway into 2027 but notes additional financing is required. The supplement also references an At-Market Issuance Sales Agreement providing up to $3.5M aggregate potential gross proceeds, with approximately $0.8M capacity remaining as of May 1, 2026.
Soligenix, Inc. files a Prospectus Supplement and Form 10-Q and registers 4,253 shares of common stock underlying previously issued common warrants.
The company reported $6,029,430 in cash and cash equivalents and a net loss of $2,824,965 for the three months ended March 31, 2026. As of May 1, 2026, 14,824,174 shares were outstanding. Management states cash runway to support operations into 2027 but also notes substantial doubt about the ability to continue as a going concern and plans to seek additional financing, including sales under an ATM facility with remaining capacity of approximately $0.8 million. The Data Monitoring Committee recommended halting the FLASH2 Phase 3 trial for futility and the company is analyzing the data to determine causes.
Soligenix, Inc. supplements its March 31, 2026 prospectus to register for resale up to 1,054,688 shares of common stock issuable upon exercise of previously issued warrants by the selling stockholders. The supplement includes the Company’s Form 10-Q for the quarter ended March 31, 2026.
Key reported figures: cash and cash equivalents of $6,029,430, a net loss of $(2,824,965) for Q1 2026, and 14,824,174 shares outstanding as of May 1, 2026. Management states cash runway to support operations into 2027 but also discloses that these factors raise substantial doubt about the Company’s ability to continue as a going concern. The prospectus supplement is a resale registration for selling holders; proceeds treatment is described in the Final Prospectus.
Operational update: the Data Monitoring Committee recommended halting the FLASH2 Phase 3 HyBryte™ trial for futility; the Company is analyzing the data.
Soligenix, Inc. filed a Prospectus Supplement registering 5,330,560 shares of common stock underlying previously issued common warrants.
The supplement, dated May 8, 2026, supplements the prospectus dated March 31, 2026 and includes the Form 10-Q for the quarter ended March 31, 2026. The filing also discloses cash and cash equivalents of $6,029,430, a net loss of $2,824,965 for the quarter, and management's statement that current resources and plans provide cash runway into 2027. As of May 1, 2026, 14,824,174 shares of common stock were outstanding.
Soligenix, Inc. is establishing an at-the-market stock offering of up to $3,450,000 of common stock under its existing shelf registration, using Rodman & Renshaw as sales agent. Shares may be sold from time to time on The Nasdaq Capital Market or other U.S. trading markets at market-related or negotiated prices, with Rodman earning up to 3.0% of the gross sales price as commission.
The company had 10,086,130 shares outstanding as of January 20, 2026, and provides an illustrative scenario of selling 2,500,000 shares at $1.38 per share, which would increase shares outstanding to 12,586,130. Net proceeds are intended to fund research and development, commercialization activities, and general corporate and working capital needs. Soligenix is a late-stage biopharmaceutical company focused on rare disease treatments, including its HyBryte photodynamic therapy program for cutaneous T‑cell lymphoma and several vaccine and biodefense candidates.
Soligenix, Inc. filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the offer and sale by the company of 408,640 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
In the 10‑Q, Soligenix reported cash and cash equivalents of $10,525,335 and stockholders’ equity of $7,597,976 as of September 30, 2025. The company recorded a net loss of $2,530,947 for Q3 2025 and $8,184,191 for the nine months ended September 30, 2025. The filing notes a completed September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.
Soligenix also disclosed it received a Nasdaq notice on August 15, 2025 regarding minimum stockholders’ equity, and believes it has since regained compliance. Shares outstanding were 10,086,130 as of October 31, 2025.
Soligenix filed a prospectus supplement registering 4,253 shares of common stock underlying previously issued common warrants. The supplement incorporates the company’s Quarterly Report on Form 10‑Q for the period ended September 30, 2025.
Cash and cash equivalents were $10,525,335, and stockholders’ equity was $7,597,976 as of September 30, 2025. The company reported a net loss of $2,530,947 for the quarter. As of October 31, 2025, 10,086,130 shares were outstanding.
Soligenix noted it had received an August 2025 Nasdaq notice regarding the equity listing standard and believes it has regained compliance following a September 29, 2025 public offering with approximately $7.5 million in gross proceeds.
Soligenix (SNGX) filed Prospectus Supplement No. 2 to its March 21, 2025 prospectus, covering the resale of up to 1,054,688 shares of common stock issuable upon exercise of previously issued common warrants by selling stockholders. The supplement incorporates the company’s Form 10‑Q for the quarter ended September 30, 2025.
As of October 31, 2025, shares outstanding were 10,086,130. For Q3 2025, the company reported a net loss of $2,530,947, and for the nine months year‑to‑date a net loss of $8,184,191. Cash and cash equivalents were $10,525,335 as of September 30, 2025, and stockholders’ equity totaled $7,597,976.
Management noted it received a Nasdaq notice on August 15, 2025 for stockholders’ equity non‑compliance and believes it regained compliance following a September 29, 2025 public offering with total gross proceeds of approximately $7.5 million.